Mitzner, S.R., Stange, J., Klammt, S., Risler, T., Erley, C.M., Bader, B.D., Berger, E.D., Lauchart, W., Peszynski, P., Freytag, J., et al. (2000) Improvement of Hepatorenal Syndrome with Extracorporeal Albumin Dialysis MARS: Results of a Prospective, Randomized, Controlled Clinical Trial. Liver Transplantation: Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 6, 277-286.

has been cited by the following article:

• TITLE: Fulminant Hepatitis: Definitions, Causes and Management

  AUTHORS: Vincenzo Morabito, Danielle Adebayo

  KEYWORDS: Fulminant Hepatitis, Liver Transplant, Liver Support, Intensive Care

  JOURNAL NAME: Health, Vol.6 No.10, April 17, 2014

  ABSTRACT: Fulminant hepatitis (FH) is a rare and devastating syndrome caused by a variety of hepatic insults. It characterized by severe metabolic derangements, neurologic complications and ultimately, multiorgan failure. Liver transplantation is the gold standard therapy for patients with irreversible FH. The major areas of current research in this field include the development of: hepatic support devices, strategies to accelerate hepatic regeneration and criteria for accurate prognostic classification of patients. This review aims to focus on the definitions, aetiologies and management strategies for FH.